Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-21-000456
Filing Date
2021-01-07
Accepted
2021-01-07 16:15:57
Documents
67
Period of Report
2020-10-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 1240185
2 ex4-2.htm EX-4.2 70568
3 ex10-10.htm EX-10.10 46043
4 ex10-13.htm EX-10.13 17484
5 ex10-14.htm EX-10.14 355794
6 ex14.htm EX-14 42046
7 ex21.htm EX-21 10689
8 ex23-1.htm EX-23.1 4712
9 ex31-1.htm EX-31.1 16475
10 ex31-2.htm EX-31.2 15317
11 ex32-1.htm EX-32.1 5588
12 ex32-2.htm EX-32.2 6148
13 ex10-10_003.jpg GRAPHIC 943
  Complete submission text file 0001493152-21-000456.txt   5039158

Data Files

Seq Description Document Type Size
14 XBRL INSTANCE FILE anix-20201031.xml EX-101.INS 729388
15 XBRL SCHEMA FILE anix-20201031.xsd EX-101.SCH 38025
16 XBRL CALCULATION FILE anix-20201031_cal.xml EX-101.CAL 51437
17 XBRL DEFINITION FILE anix-20201031_def.xml EX-101.DEF 169185
18 XBRL LABEL FILE anix-20201031_lab.xml EX-101.LAB 322376
19 XBRL PRESENTATION FILE anix-20201031_pre.xml EX-101.PRE 250640
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-K | Act: 34 | File No.: 001-37492 | Film No.: 21514371
SIC: 2834 Pharmaceutical Preparations